Compare Regeneron Pharmaceuticals Inc (REGN) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Yum! Brands, Inc. — how do they compare? Regeneron Pharmaceuticals Inc trades at $740 (market cap $76.14B), while Yum! Brands, Inc. trades at $143 (market cap $39.02B). The key difference: Regeneron Pharmaceuticals Inc is the larger of the two by market cap, and Yum! Brands, Inc. pays the higher dividend (2.1%). Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Yum! Brands, Inc. for 132 Days on average.
| REGN | YUM | |
|---|---|---|
Market Cap | $76.14B | $39.02B |
Volume | 500,239 | 2,597,636 |
Sector | Health | Consumer Cyclical |
52-Week High | $852.03 | $168.16 |
52-Week Low | $557.73 | $135.77 |
Typical Hold Time | 107 Days | 132 Days |
Enterprise Value | $70.85B | $50.63B |
Dividend Yield | 0.51% | 2.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
YUM Brands trades at $140.35, up 0.36% today, with mixed technical signals showing bullish overall but bearish moving averages. The company demonstrates strong fundamentals with 2025 revenue of $8.21B and net income of $1.56B, though recent earnings show mixed quarterly performance. YUM completed the Pizza Hut sale for approximately $1.5B in September 2026, focusing on core brands KFC and Taco Bell.
YUM presents a compelling opportunity with analyst consensus target of $170.44 (21% upside), supported by consistent cash flow growth and strategic brand focus. Key risks include high debt levels ($11.25B long-term) and competitive pressures in the QSR space. The stock offers dividend stability with nine consecutive years of increases.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
